[Pulmonary mucormycosis: benefit of aerosol amphotericin B?].
Mucormycosis is an opportunistic fungal infection usually observed in diabetic or neutropenic patients. Prognosis is serious with a high rate of mortality. Intravenous amphotericin B is the gold standard treatment. The main side effect is renal failure. Liposomal amphotericin B (AmBisome(R)) is not nephrotoxic and can be proposed as an alternative treatment although its cost is high. We report a case of mucormycosis in a diabetic woman who developed renal failure after intravenous amphotericin B treatment. AmBisome(R) could not be used for long-term treatment due to its high case. The patient was given nebulized amphotericin B and achieved recovery. This kind of treatment may provide a useful alternative to intravenous amphotericin B.
Furco
A
A
Laboratoire de Bactériologie-Virologie-Hygiène, CHU Robert Debré, rue Alexis Carrel 51092 Reims Cedex.
Mouchet
B
B
Carbonnelle
M
M
Vallerand
H
H
D000280:Administration, Inhalation; D000336:Aerosols; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000473:pathology; D009091:Mucormycosis / Q000188:drug therapy* / Q000473:pathology; D009330:Nebulizers and Vaporizers; D051437:Renal Insufficiency / Q000139:chemically induced*
D000336:Aerosols; D000935:Antifungal Agents; D000666:Amphotericin B